Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up
The objective of this study was to determine the impact of a pharmaceutical care (PC) program in a sample of public outpatients with metabolic syndrome (MS) who were being treated in Brazil's health system; the patients were randomized into PC or standard care. The pharmacotherapy follow-up (PF) was performed in a total of 120 patients with type 2 diabetes for 6 months. Adherence to treatment (measured with the Morisky test), negative outcomes associated with medication (NOM) and anthropometric and biochemical parameters were measured before and after PF. The Framingham scoring method was used to estimate changes in 10-year coronary heart disease risk scores in all patients. Ninety-six of 120 patients had characteristics of MS and were randomized into two groups (G): the control group (CG: 36) and the intervention group (IG: 38). Among the MS patients, 100% were taking a glucose-lowering drug; many were also taking anti-hypertensive drugs (CG: 72%; IG: 73%), and some patients were also taking hypolipemic drugs (CG: 12.0%; IG: 14.7%). Only 20.7% of the IG patients were considered adherent to their prescribed drugs. In the CG, an increase of coronary heart disease (CHD) risk (22±2 to 26±3; p<0.05) was observed, while in the IG, there was a reduction in CHD risk (22±2 to 14±2%; p<0.01). The PC program administered to patients with MS monitored through the primary healthcare services of the Brazilian public health system improved patient health, resulting in clinical improvements and a decrease in cardiovascular risk in IG patients over a period of ten years.
Main Authors: | , , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Universidade de São Paulo, Faculdade de Ciências Farmacêuticas
2012
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502012000300010 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S1984-82502012000300010 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S1984-825020120003000102012-10-18Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-upPlaster,Camila PedroMelo,Danilo TravassosBoldt,VeraciCassaro,Karla Oliveira dos SantosLessa,Fernanda Campos RosettiBoëchat,Giovanna Assis PereriraBissoli,Nazaré SouzaAndrade,Tadeu Uggere de Pharmaceutical service Metabolic syndrome/cardiovascular risk Drug therapy follow-up Medicines/associated negative outcomes The objective of this study was to determine the impact of a pharmaceutical care (PC) program in a sample of public outpatients with metabolic syndrome (MS) who were being treated in Brazil's health system; the patients were randomized into PC or standard care. The pharmacotherapy follow-up (PF) was performed in a total of 120 patients with type 2 diabetes for 6 months. Adherence to treatment (measured with the Morisky test), negative outcomes associated with medication (NOM) and anthropometric and biochemical parameters were measured before and after PF. The Framingham scoring method was used to estimate changes in 10-year coronary heart disease risk scores in all patients. Ninety-six of 120 patients had characteristics of MS and were randomized into two groups (G): the control group (CG: 36) and the intervention group (IG: 38). Among the MS patients, 100% were taking a glucose-lowering drug; many were also taking anti-hypertensive drugs (CG: 72%; IG: 73%), and some patients were also taking hypolipemic drugs (CG: 12.0%; IG: 14.7%). Only 20.7% of the IG patients were considered adherent to their prescribed drugs. In the CG, an increase of coronary heart disease (CHD) risk (22±2 to 26±3; p<0.05) was observed, while in the IG, there was a reduction in CHD risk (22±2 to 14±2%; p<0.01). The PC program administered to patients with MS monitored through the primary healthcare services of the Brazilian public health system improved patient health, resulting in clinical improvements and a decrease in cardiovascular risk in IG patients over a period of ten years.info:eu-repo/semantics/openAccessUniversidade de São Paulo, Faculdade de Ciências FarmacêuticasBrazilian Journal of Pharmaceutical Sciences v.48 n.3 20122012-09-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502012000300010en10.1590/S1984-82502012000300010 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Plaster,Camila Pedro Melo,Danilo Travassos Boldt,Veraci Cassaro,Karla Oliveira dos Santos Lessa,Fernanda Campos Rosetti Boëchat,Giovanna Assis Pererira Bissoli,Nazaré Souza Andrade,Tadeu Uggere de |
spellingShingle |
Plaster,Camila Pedro Melo,Danilo Travassos Boldt,Veraci Cassaro,Karla Oliveira dos Santos Lessa,Fernanda Campos Rosetti Boëchat,Giovanna Assis Pererira Bissoli,Nazaré Souza Andrade,Tadeu Uggere de Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up |
author_facet |
Plaster,Camila Pedro Melo,Danilo Travassos Boldt,Veraci Cassaro,Karla Oliveira dos Santos Lessa,Fernanda Campos Rosetti Boëchat,Giovanna Assis Pererira Bissoli,Nazaré Souza Andrade,Tadeu Uggere de |
author_sort |
Plaster,Camila Pedro |
title |
Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up |
title_short |
Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up |
title_full |
Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up |
title_fullStr |
Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up |
title_full_unstemmed |
Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up |
title_sort |
reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up |
description |
The objective of this study was to determine the impact of a pharmaceutical care (PC) program in a sample of public outpatients with metabolic syndrome (MS) who were being treated in Brazil's health system; the patients were randomized into PC or standard care. The pharmacotherapy follow-up (PF) was performed in a total of 120 patients with type 2 diabetes for 6 months. Adherence to treatment (measured with the Morisky test), negative outcomes associated with medication (NOM) and anthropometric and biochemical parameters were measured before and after PF. The Framingham scoring method was used to estimate changes in 10-year coronary heart disease risk scores in all patients. Ninety-six of 120 patients had characteristics of MS and were randomized into two groups (G): the control group (CG: 36) and the intervention group (IG: 38). Among the MS patients, 100% were taking a glucose-lowering drug; many were also taking anti-hypertensive drugs (CG: 72%; IG: 73%), and some patients were also taking hypolipemic drugs (CG: 12.0%; IG: 14.7%). Only 20.7% of the IG patients were considered adherent to their prescribed drugs. In the CG, an increase of coronary heart disease (CHD) risk (22±2 to 26±3; p<0.05) was observed, while in the IG, there was a reduction in CHD risk (22±2 to 14±2%; p<0.01). The PC program administered to patients with MS monitored through the primary healthcare services of the Brazilian public health system improved patient health, resulting in clinical improvements and a decrease in cardiovascular risk in IG patients over a period of ten years. |
publisher |
Universidade de São Paulo, Faculdade de Ciências Farmacêuticas |
publishDate |
2012 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502012000300010 |
work_keys_str_mv |
AT plastercamilapedro reductionofcardiovascularriskinpatientswithmetabolicsyndromeinacommunityhealthcenterafterapharmaceuticalcareprogramofpharmacotherapyfollowup AT melodanilotravassos reductionofcardiovascularriskinpatientswithmetabolicsyndromeinacommunityhealthcenterafterapharmaceuticalcareprogramofpharmacotherapyfollowup AT boldtveraci reductionofcardiovascularriskinpatientswithmetabolicsyndromeinacommunityhealthcenterafterapharmaceuticalcareprogramofpharmacotherapyfollowup AT cassarokarlaoliveiradossantos reductionofcardiovascularriskinpatientswithmetabolicsyndromeinacommunityhealthcenterafterapharmaceuticalcareprogramofpharmacotherapyfollowup AT lessafernandacamposrosetti reductionofcardiovascularriskinpatientswithmetabolicsyndromeinacommunityhealthcenterafterapharmaceuticalcareprogramofpharmacotherapyfollowup AT boechatgiovannaassispererira reductionofcardiovascularriskinpatientswithmetabolicsyndromeinacommunityhealthcenterafterapharmaceuticalcareprogramofpharmacotherapyfollowup AT bissolinazaresouza reductionofcardiovascularriskinpatientswithmetabolicsyndromeinacommunityhealthcenterafterapharmaceuticalcareprogramofpharmacotherapyfollowup AT andradetadeuuggerede reductionofcardiovascularriskinpatientswithmetabolicsyndromeinacommunityhealthcenterafterapharmaceuticalcareprogramofpharmacotherapyfollowup |
_version_ |
1756437750706339840 |